Favipiravir, lopinavir-ritonavir, or combination therapy (FLARE): A randomised, double-blind, 2 × 2 factorial placebo-controlled trial of early antiviral therapy in COVID-19. (2022)
Attributed to:
MICA: Pharmacokinetic/Pharmacodynamic (PKPD) Model Development to Inform SARS-CoV-2 Antiviral Development
funded by
COVID
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1371/journal.pmed.1004120
PubMed Identifier: 36260627
Publication URI: http://europepmc.org/abstract/MED/36260627
Type: Journal Article/Review
Volume: 19
Parent Publication: PLoS medicine
Issue: 10
ISSN: 1549-1277